For example, immunotherapy with immune checkpoint inhibitors such as programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) inhibitors has shown satisfying outcomes in multiple cancer types including lung cancer (7). Here, PDCD1 is linked to lung carcinoma.